Next Article in Journal
Doxorubicin-Loaded PEG-PCL-PEG Micelle Using Xenograft Model of Nude Mice: Effect of Multiple Administration of Micelle on the Suppression of Human Breast Cancer
Next Article in Special Issue
Screening Technologies for Target Identification in Pancreatic Cancer
Previous Article in Journal
Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics
Previous Article in Special Issue
The Role of Apoptosis in the Pathology of Pancreatic Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(1), 43-60;

Pain Management in Pancreatic Cancer

Department of Physical Medicine and Rehabilitation, School of Medicine, Johns Hopkins University, 600 N. Wolfe St., Phipps 160, Baltimore, MD 21287, USA
Division of Pain Medicine, Department of Anesthesia and Critical Care Medicine, Johns Hopkins University, School of Medicine, 550 North Broadway St., Suite 301, Baltimore, MD 21205, USA
Author to whom correspondence should be addressed.
Received: 1 November 2010 / Revised: 25 November 2010 / Accepted: 20 December 2010 / Published: 24 December 2010
(This article belongs to the Special Issue Pancreatic Cancer)
Full-Text   |   PDF [180 KB, uploaded 24 December 2010]


A majority of pancreatic cancer patients present with pain at the time of diagnosis. Pain management can be challenging in light of the aggressive nature of this cancer. Apart from conventional pharmacotherapy, timely treatment with neurolytic celiac plexus block (NCPB) has been shown to be of benefit. NCPB has demonstrated efficacious pain control in high quality studies with analgesic effects lasting one to two months. NCPB has also shown to decrease the requirements of narcotics, and thus decrease opioid related side effects. Another option for the control of moderate to severe pain is intrathecal therapy (IT). Delivery of analgesic medications intrathecally allows for lower dosages of medications and thus reduced toxicity. Both of the above mentioned interventional procedures have been shown to have low complication rates, and be safe and effective. Ultimately, comprehensive pancreatic cancer pain management necessitates understanding of pain mechanisms and delivery of sequential validated therapeutic interventions within a multidisciplinary patient care model. View Full-Text
Keywords: pancreatic cancer; neurolytic celiac plexus block; intrathecal therapy; opioids; pain pancreatic cancer; neurolytic celiac plexus block; intrathecal therapy; opioids; pain
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Hameed, M.; Hameed, H.; Erdek, M. Pain Management in Pancreatic Cancer. Cancers 2011, 3, 43-60.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top